The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Yingying MaoYong Zhu

Abstract

Although the role of core circadian gene cryptochrome 2 (CRY2) in breast tumorigenesis has been demonstrated, the correlations of CRY2 with clinical parameters in breast cancer patients and its involvement in epigenetic processes such as DNA methylation remain relatively unexplored. In the current study, we first queried the Oncomine database and the Gene Expression-Based Outcome for Breast Cancer Online (GOBO) database to identify associations between CRY2 expression levels and clinical parameters in breast cancer patients. We then silenced CRY2 in vitro and performed a genome-wide methylation array to determine the epigenetic impact of CRY2 silencing. The Ingenuity Pathway Analysis software was used to further explore the genes exhibiting altered methylation identified using the array. We found that CRY2 was frequently down-regulated in breast cancer tissue compared to adjacent normal tissue or breast tissue from healthy controls. Lower CRY2 expression was associated with estrogen receptor (ER)-negativity (P < 0.0001), higher tumor grade (P < 0.0001), and shorter overall survival time in breast cancer patients (HR = 1.44, 95 % confidence interval (CI) 1.09-1.91). Genome-wide methylation analysis showed that a total of 515 CpG...Continue Reading

References

Aug 29, 2002·Nature·Steven M Reppert, David R Weaver
May 2, 2003·Nature Reviews. Cancer·Loning Fu, Cheng Chi Lee
Mar 23, 2004·Molecular Biology of the Cell·Hongjuan ZhaoStefanie S Jeffrey
Sep 2, 2004·Journal of Molecular Histology·R Marhaba, M Zöller
Mar 31, 2005·Molecular and Cellular Biology·Keziban Unsal-KaçmazAziz Sancar
Jul 27, 2005·Proceedings of the National Academy of Sciences of the United States of America·Laszlo RadvanyiNeil L Berinstein
Aug 3, 2005·Cancer Research·Michele A Gauger, Aziz Sancar
Sep 2, 2005·Nature·Steve E CalvanoUNKNOWN Inflamm and Host Response to Injury Large Scale Collab. Res. Program
Feb 14, 2006·Cancer Cell·Andrea L RichardsonShridar Ganesan
Oct 27, 2006·Molecular Biology of the Cell·Véronique Orian-RousseauHelmut Ponta
Mar 7, 2007·Current Topics in Developmental Biology·Roman V KondratovMarina P Antoch
Mar 16, 2007·Neoplasia : an International Journal for Oncology Research·Daniel R RhodesArul M Chinnaiyan
Oct 5, 2007·Nature·Antoine E KarnoubRobert A Weinberg
Mar 13, 2008·Journal of Circadian Rhythms·Shulin XiangSteven M Hill
Apr 29, 2008·Nature Medicine·Greg FinakMorag Park
Feb 4, 2009·Breast Cancer Research : BCR·Xiao-Jun MaDennis C Sgroi
Oct 7, 2009·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Kazuharu KaiHideyuki Saya
Mar 30, 2011·PloS One·Markus RingnérJohan Staaf
Oct 6, 2011·Molecular Cancer Research : MCR·Jeanne M V Louderbough, Joyce A Schroeder
Jul 13, 2013·Cancer Cell·François VaillantGeoffrey J Lindeman

❮ Previous
Next ❯

Citations

Apr 25, 2019·Chronobiology International·Mengjun QiuSheng-Li Yang
Jun 4, 2019·International Journal of Molecular Sciences·Sadia RahmanElitza Markova-Car
Feb 13, 2018·Molecular and Clinical Oncology·Minou NirvaniAmer Sehic
Nov 7, 2017·Chronobiology International·Agnieszka Bukowska-DamskaBeata Peplonska
Oct 30, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sadia RahmanElitza P Markova-Car
Aug 10, 2021·Chronobiology International·Nidhi NagariyaVihas T Vasu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.